Cardiovascular Pathology
Volume 20, Issue 2 , Pages 84-92 , March 2011

Statin treatment of hypercholesterolemic-induced aortic valve sclerosis

  • Amanda M. Hamilton

      Affiliations

    • Department of Anatomy and Cell Biology, Schulich School of Medicine and Dentistry, The University of Western Ontario, London, ON, Canada
    • Imaging Research Laboratories, Robarts Research Institute, The University of Western Ontario, London, ON, Canada
    • ,
  • Derek R. Boughner

      Affiliations

    • Department of Anatomy and Cell Biology, Schulich School of Medicine and Dentistry, The University of Western Ontario, London, ON, Canada
    • Department of Medicine, Schulich School of Medicine and Dentistry, The University of Western Ontario, London, ON, Canada
    • Imaging Research Laboratories, Robarts Research Institute, The University of Western Ontario, London, ON, Canada
    • ,
  • Maria Drangova

      Affiliations

    • Department of Medical Biophysics, Schulich School of Medicine and Dentistry, The University of Western Ontario, London, ON, Canada
    • Imaging Research Laboratories, Robarts Research Institute, The University of Western Ontario, London, ON, Canada
    • ,
  • Kem A. Rogers

      Affiliations

    • Department of Anatomy and Cell Biology, Schulich School of Medicine and Dentistry, The University of Western Ontario, London, ON, Canada
    • Corresponding Author InformationCorresponding author. Department of Anatomy and Cell Biology, The University of Western Ontario, MSB M426, London, ON, Canada N6A 5C1. Tel.: +1 519 661 3995; fax: +1 519 661 3936.

Received 3 June 2009 ,Revised 8 December 2009 ,Accepted 5 January 2010.

References 

  1. Stewart MD, Siscovick MD, Lind MS, Gardin MD, Gottdiener MD, Smith MD, et al. Clinical factors associated with calcific aortic valve disease. J Am Coll Cardiol. 1997;29(3):630–634
  2. O'Brien KD. Pathogenesis of calcific aortic valve disease: a disease process comes of age (and a good deal more). Arterioscler Thromb Vasc Biol. 2006;26(8):1721–1728
  3. Lindroos M, Kupari M, Heikkila J, Tilvis R. Prevalence of aortic valve abnormalities in the elderly: an echocardiographic study of a random population sample. J Am Coll Cardiol. 1993;21(5):1220–1225
  4. Otto C, Kuusisto J, Reichenbach D, Gown A, O'Brien KD. Characterization of the early lesion of ‘degenerative’ valvular aortic stenosis. Histological and immunohistochemical studies. Circulation. 1994;90(2):844–853
  5. Goldbarg SH, Elmariah S, Miller MA, Fuster V. Insights into degenerative aortic valve disease. J Am Coll Cardiol. 2007;50(13):1205–1213
  6. Antonini-Canterin F, Popescu BA, Huang G, Korcova-Miertusova R, Rivaben D, Faggiano P, et al. Progression of aortic valve sclerosis and aortic valve stenosis: what is the role of statin treatment?. Ital Heart J. 2005;6(2):119–124
  7. Antonini-Canterin F, Hîrşu M, Popescu BA, Leiballi E, Piazza R, Pavan D, et al. Stage-related effect of statin treatment on the progression of aortic valve sclerosis and stenosis. Am J Cardiol. 2008;102(6):738–742
  8. Cowell SJ, Newby DE, Prescott RJ, Bloomfield P, Reid J, Northridge DB, et al. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med. 2005;352(23):2389–2397
  9. Rossebo AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med. 2008;359(13):1343–1356
  10. Moura LM, Ramos SF, Zamorano JL, Barros IM, Azevedo LF, Rocha-Gon alves F, et al. Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis. J Am Coll Cardiol. 2007;49(5):554–561
  11. Rajamannan NM, Subramaniam M, Springett M, Sebo TC, Niekrasz M, McConnell JP, et al. Atorvastatin inhibits hypercholesterolemia-induced cellular proliferation and bone matrix production in the rabbit aortic valve. Circulation. 2002;105(22):2660–2665
  12. Rajamannan NM, Subramaniam M, Stock SR, Stone NJ, Springett M, Ignatiev KI, et al. Atorvastatin inhibits calcification and enhances nitric oxide synthase production in the hypercholesterolaemic aortic valve. Heart. 2005;91(6):806–810
  13. Rajamannan NM, Subramaniam M, Caira F, Stock SR, Spelsberg TC. Atorvastatin inhibits hypercholesterolemia-induced calcification in the aortic valves via the Lrp5 receptor pathway. Circulation. 2005;112(9):I229–234
  14. Hamilton A, Rogers K, Drangova M, Khan Z, Ronald J, Rutt B, et al. The in vivo diagnosis of early stage aortic valve sclerosis using magnetic resonance imaging in a rabbit model. J Magn Reson Imaging. 2009;29(4):825–831
  15. Cimini M, Boughner D, Ronald J, Aldington L, Rogers K. Development of aortic valve sclerosis in a rabbit model of atherosclerosis: an immunohistochemical and histological study. J Heart Valve Dis. 2005;14(3):365–375
  16. Kapur N, Musunuru K. Clinical efficacy and safety of statins in managing cardiovascular risk. Vasc Health Risk Manag. 2008;4(2):341–353
  17. Luan Z, Chase AJ, Newby AC. Statins inhibit secretion of metalloproteinases-1, -2, -3, and -9 from vascular smooth muscle cells and macrophages. Arterioscler Thromb Vasc Biol. 2003;23(5):769–775
  18. Marcel YL, Ouimet M, Wang MD. Regulation of cholesterol efflux from macrophages. Curr Opin Lipidol. 2008;19(5):455–461
  19. Rajamannan NM, Subramaniam M, Rickard D, Stock SR, Donovan J, Springett M, et al. Human aortic valve calcification Is associated with an osteoblast phenotype. Circulation. 2003;107(17):2181–2184
  20. Steitz SA, Speer MY, McKee MD, Liaw L, Almeida M, Yang H, et al. Osteopontin inhibits mineral deposition and promotes regression of ectopic calcification. Am J Pathol. 2002;161(6):2035–2046

 Financial support: This work was funded by the Heart and Stroke Foundation of Ontario [T6332]. M.D. is a Career Investigator of the Heart and Stroke Foundation of Ontario.

PII: S1054-8807(10)00020-7

doi: 10.1016/j.carpath.2010.01.004

Cardiovascular Pathology
Volume 20, Issue 2 , Pages 84-92 , March 2011

Article Tools

* Image Usage & Resolution